drugset / Trial / NCT01090154
Study of Cimzia for the Treatment of Ulcerative Colitis
Phase 2
Completed
27 enrolled
University of Washington
UCB Pharma · collabUniversity of Pennsylvania · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if Cimzia (certolizumab pegol) is an effective treatment for patients with Ulcerative colitis.
Timeline
- Start
- 2010-12-01
- Primary completion
- 2021-12-10
- Completion
- 2021-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Certolizumab Pegol | Protein / enzyme biologic | 400 mg | Subcutaneous |